Original Article
Modulation of the lung RNAome in a metabolic syndrome rat model

Sofía M Rodríguez-Peredo1,2, Ashley K Castellanos-Jankiewicz1, Iván Imaz-Rosshandler1, Miguel Á Espinoza-Camacho1,2, Claudia Rangel-Escareño4, José L Muñoz-Sánchez3, Jorge Meléndez-Zajgla5, M Elizabeth Tejero1, Roxana Carbó3, Vilma Maldonado6, Laura del Bosque-Plata1


Received September 9, 2016; Accepted December 10, 2016; Epub May 1, 2017; Published May 15, 2017

Abstract: Metabolic syndrome (MetS) is characterized by a constellation of conditions that increase the risk for heart disease and other health problems. Although multiple organs are affected by this syndrome, research that focuses on the organs that are not directly involved in metabolism is lacking. Because MetS increases the risk for various lung diseases, we explored the effects of MetS on the lung in this study. We observed that the chronic consumption of a high sucrose diet for 24 weeks induced MetS in a rat model. Concomitant expression changes in 1,026 coding genes and two microRNAs were observed in the analyzed lung tissues. A network analysis showed degradation changes in the melatonin pathway, which plays a protective role in the lung; impairments of several inflammatory pathways (i.e., interferon-γ and nuclear factor kappa B) were also revealed. Moreover, multiple olfactory genes were unexpectedly deregulated. Overall, the lungs of MetS mice exhibited an inflammatory phenotype with molecular changes that affected several signaling pathways that were related to melatonin metabolism, olfactory receptors and cytokine production. Additional research will be necessary to dissect a possible mechanism for the effects of this syndrome on the lung.

Keywords: Metabolic syndrome, lung, rats, RNAome, high sucrose diet

Introduction

Metabolic syndrome (MetS) is a cluster of risk factors that contribute to the development of diabetes mellitus and/or cardiovascular disease. According to the International Diabetes Federation (IDF), this cluster is characterized by central obesity, insulin resistance (IR), dyslipidemia (elevated triglyceride and low density lipoprotein levels and decreased high density lipoprotein levels), and high blood pressure [1]. This syndrome may result from an unbalanced diet that is high in fat and carbohydrates, along with the patient’s genetic background [2, 3]. Adipose tissue serves as an energy storage mechanism and exhibits endocrine functions. Adipose tissue cells secrete adipokines that are involved in regulating appetite, satiety, inflammation, and insulin sensitivity. The effects of adipokines on the circulating levels of leptin and adiponectin during obesity are well known. Several adipokines also play important roles in establishing low-grade chronic inflammation; adipocytes and other cells that are present in adipose tissue secrete pro-inflammatory cytokines, which produce various effects throughout the body [2-5].
Changes in insulin signaling during MetS have direct effects on vascular endothelial cells; this extends beyond the regulation of blood flow and includes abnormal cellular signaling in the arteries and in other cell types. These changes contribute to the development of heart disease. Similarly, MetS creates an important dysfunction in pancreatic β cells that leads to type 2 diabetes [6, 7]. This syndrome also has various effects on other organs, such as the liver and kidney. Consequently, MetS strongly contributes to the prevalence of non-communicable diseases, such as cardiovascular disease, type 2 diabetes, non-alcoholic liver disease, and cancer [6, 8-10].

Evidence suggests that MetS is a condition that increases the risk for different lung diseases. Diminished lung functions have been reported in several MetS patients who were assessed by spirometry. Additionally, there are associations with insulin resistance (IR), an increase in body mass index (BMI), abdominal obesity and systemic inflammation (i.e., high levels of C reactive protein) [11-13]. Various features of MetS, such as abdominal obesity, hypertension and pro-inflammatory cytokines, have been associated with diseases such as asthma [14-16]. Additionally, several clinical studies have reported that abdominal obesity, hyperglycemia and elevated levels of systemic inflammatory markers, which are components of MetS, are significantly more prevalent in patients with chronic obstructive pulmonary disease [17-20].

Finally, the mechanisms and endocrine alterations that may elicit specific changes to cellular signaling and gene expression, which would potentially contribute to the increased risk of lung diseases in patients with MetS, remain unknown. In this study, we evaluated morphological and transcriptomic changes in the lung tissues of a diet-induced animal model for MetS.

**Table 1.** Physiological parameters

<table>
<thead>
<tr>
<th></th>
<th>Control n=12</th>
<th>MetS n=12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (g)</td>
<td>536.3 ± 13</td>
<td>482.6 ± 19</td>
</tr>
<tr>
<td>Blood pressure (mmHg)</td>
<td>121.1 ± 4.16</td>
<td>129.4 ± 4.0</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>89.2 ± 6</td>
<td>88.5 ± 7.1</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>68.5 ± 4.6</td>
<td>52.3 ± 5.3**</td>
</tr>
<tr>
<td>HDL-Cholesterol (mg/dL)</td>
<td>46.33 ± 3.2</td>
<td>31.1 ± 3.3***</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>87.8 ± 4.9</td>
<td>136.6 ± 15.07**</td>
</tr>
<tr>
<td>Insulin (µU/mL)</td>
<td>3.7 ± 0.9</td>
<td>5.2 ± 0.7</td>
</tr>
<tr>
<td>Adiponectin (µg/mL)</td>
<td>14.2 ± 1.2</td>
<td>33.6 ± 3.6***</td>
</tr>
<tr>
<td>Leptin (ng/mL)</td>
<td>0.6 ± 0.06</td>
<td>1.4 ± 0.2**</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.8 ± 0.2</td>
<td>1.1 ± 0.1</td>
</tr>
</tbody>
</table>

Each value is presented as the mean plus or minus the standard error (S.E.). **P<0.01; ***P<0.001. HDL: high density lipoproteins; HOMA: Homeostasis Model Assessment.

The high sucrose diet promoted a redistribution of the retroperitoneal adipose tissue with increased deposits of adipose tissue (AT) to areas around the heart and thoracic cavity, the sternum, and between the lung lobes. Several of these animals contained small lesions in their lung tissues ([Figure 1A](#)).

The dietary composition plays important roles in the onsets of specific diseases, such as diabetes, obesity and MetS [22, 23]. In our model, the appearance of dyslipidemia and the accumulation of AT confirmed that the high sucrose intake induced metabolic changes in the liver and led to an AT redistribution. Thus, this model achieved at least three IDF criteria [1] and consequently fulfilled the proposed criteria that were established by Kennedy et al. in 2010 for a definition of MetS for rodents [24].

Additionally, histological staining revealed that the lungs from the MetS group exhibited...
increased inflammatory foci with areas of lymphocyte infiltration (Figure 1B) relative to the CTL group. Seven rats (7 out of 7) with MetS were positive for RO staining, which confirmed the presence of the lipid content, and most samples were positive for macrophages (Figure 1C). One case in the control group was RO positive (1 of 7).

Abnormalities in lipid metabolism have been associated with various pulmonary diseases, including chronic obstructive pulmonary disease (COPD) and lung cancer [25, 26]. AT contributes to systemic pro-inflammatory effects through adipokine secretion. The altered AT deposition (adjacent to the thoracic cage and pericardium) may locally contribute, per se, to a deregulation
of tissue physiology and molecular pathways by mechanical and paracrine factors. In COPD patients, the tissue secretions of these cytokines correlate with disease severity [27].
Lung RNAome modulation in metabolic syndrome

Table 2. Top 5 canonical pathways

<table>
<thead>
<tr>
<th>Name</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melatonin degradation I</td>
<td>4.87E-03</td>
</tr>
<tr>
<td>Super pathways of melatonin degradation II</td>
<td>7.35E-03</td>
</tr>
<tr>
<td>Thyroid hormone metabolism II</td>
<td>1.56E-02</td>
</tr>
<tr>
<td>Nicotine degradation III</td>
<td>1.67E-02</td>
</tr>
<tr>
<td>Nicotine degradation II</td>
<td>3.04E-02</td>
</tr>
</tbody>
</table>

Adiponectin and leptin molecules modulate innate and adaptive immune responses [3, 28]. Multiple studies have identified a relationship between the severity of the decrease in lung function that is associated with several conditions, such as asthma and COPD, and high levels of these adipokines [13, 27, 29-32]. Otabe et al. showed that hyperadiponectinemia has anti-inflammatory effects and may slow the acceleration of the aging process that is associated with metabolic syndrome by inhibiting AKT signaling, thereby attenuating the chronic low-grade inflammation that is attributed to the syndrome [33].

To the best of our knowledge, this is the first report to demonstrate that the ingestion of a high sucrose diet promotes important lung tissue alterations. Although it remains unknown, one possible mechanism for these findings may involve the high levels of carbon dioxide that are produced by sucrose metabolism, which would trigger different cell signaling cascades to promote an inflammatory response. In patients with COPD, the international dietary recommendation indicates that the intake of simple carbohydrates should be reduced to improve lung health [34]. Forno E et al. have recently shown that obesity, insulin resistance, and metabolic syndrome may lead to a worsening of lung functions in adolescents with and without asthma. Further research will be needed to understand the underlying causes of these associations [35].

We also analyzed gene expression changes in the lung samples of the rats that were exposed to sucrose. The principal component analysis graph in Figure 2A shows two sample groups; each group is differentiated by its global gene expression pattern. After normalization of the raw data using the standard robust-multi-array average (RMA) method, a major subexpression of the total transcript number in the lungs from MetS was identified (volcano plot, Figure 2B). In one comparison, 1,026 genes were differentially expressed between the MetS and CTL groups. Thirteen genes were up-regulated, and 1,013 genes were down-regulated, with a p-value <0.02 and a log FC>0.58 (Figure 2C). To validate the microarray data, we measured the expression of 8 genes by qRT-PCR (Figure 2D).

We identified two deregulated miRNAs (mir-653 and mir-489) with a log FC=-0.5, mir-653 is associated with fetal lung development in Sprague-Dawley rats [36], and mir-489 has a potential role in the development of non-small cell lung cancer. Inhibition of the latter promotes cell invasion and regulates the epithelial mesenchymal transition (EMT) in rats [37]. Figure 2E shows a heat map of the genes that were deregulated in the two experimental groups, and Figure 2F shows the chromosome positions and log FC values of the deregulated miRNAs. The prediction analysis shows 331 transcripts with conserved sites for miR-653-5p and 209 transcripts with conserved sites for mir-489-3p [38]. It will be necessary to conduct further studies regarding the metabolic pathways that are regulated by these miRNAs to better understand the mechanisms that underlie genomic lung transcription.

We performed an enrichment analysis with these data using the IPA software. Table 2 shows that the melatonin degradation pathway 1 and the melatonin super pathway of degradation 2 were among the top 5 pathways. Melatonin is a widely distributed hormone that plays functional roles in determining sleep patterns and circadian synchronization. Melatonin also exhibits antioxidant activity. In addition to its role as an activator and antioxidant enzyme, it acts as a major, direct scavenger of free radicals [39-42].

The possible involvement of melatonin in the genesis of MetS-mediated lung alterations is indirectly supported by several previous studies. In 2012, Matos et al. found that a melatonin treatment reduced lung oxidative stress and improved dyspnea in a randomized, double-blind, placebo-controlled study of COPD patients [43]. Additionally, Baik et al., demonstrated that melatonin had a protective effect against lung inflammation after measuring pro-inflammatory cytokine levels (i.e., interleukin (IL)-1B, IL-6, tumor necrosis factor (TNF)-alpha, interferon gamma (IFN-γ)) and leukocyte accumulation in the serum and Broncho alveolar lavage fluid (BALF) of mice with lipopolysaccha-
Lung RNAome modulation in metabolic syndrome
Figure 3. Deregulated transduction pathways in MetS. A: Melatonin degradation pathway; B: Deregulated genes in IFN-γ pathway; C: Deregulated genes in the nuclear factor kappa B pathway; D: Genes that were deregulated by progesterone. Green indicates down-regulation of expression, and blue represents the predicted function of the gene.
Lung RNAome modulation in metabolic syndrome

ride- and sleep deprivation-induced lung inflammation [44]. This may support the notion that a protective pathway is activated as a consequence of the syndrome.

Endogenous melatonin in the lungs reduces oxygen-induced oxidative stress in rats [45]. Generally, melatonin is beneficial to inflammation in lung diseases [43]. However, we hypothesize that the involvement of the deregulated melatonin degradation pathway may affect the lungs through the serotonin pathway because several of the deregulated enzyme transcripts (Figure 3A) also affect serotonin production and processing; serotonin is a critical hormone to lung endothelial function [46]. Our results are the first to demonstrate that the deregulation of the melatonin pathway in MetS is potentially associated with pulmonary alterations.

Similarly, we identified several deregulated molecules that were associated with inflammatory pathways, including the histocompatibility complex (MHC), zinc finger and BTB domain containing 16 (ZBTB16), and chemokine (C-C motif) receptor 3 (CCR3); they are linked to the IFN-γ pathway (Figure 3B). We also identified several other deregulated genes, including the vomeronasal receptors (vmnrs) (Figure 3C). These receptors are indirectly associated with the nuclear factor kappa B (NF-κB) pathway, and this transcription factor may be involved in the inflammatory responses of the lungs in the MetS rats. Notably, several genes that are regulated by progesterone and glucocorticoids were also altered in the MetS rat lungs in the microarray analysis (Figure 3D), which highlighted the complexity of the hormonal deregulation.

Surprisingly, 733 olfactory receptor (Olfr) genes were down-regulated in the MetS lung tissue (Supplementary Table 1). Among the top 10 down-regulated genes, 5 of the 10 transcripts
were for Olfrs. These genes can be regulated by the paired box 6 (Pax6) transcription factor or by the glutathione S-transferase fusion protein (Gst) (Figure 4A-C). This deregulation may be due to a general inactivation of their transcriptional regulator(s). Alternatively, the deregulation may reflect a change in the number of pulmonary neuroendocrine cells, which are the main Olfr-expressing cells in the lung. Because these cells are potentially responsible for the chemical hypersensitivity feature of several lung diseases, such as COPD, this down-regulation may be related to receptor desensitization or a decrease in the Olfr-expressing cell number in animals with MetS. Further experiments are needed to explore these possibilities.

Ghrelin is another noteworthy molecule that appears among the top upstream regulators (Supplementary Table 2). This peptide influences energy balance and has been detected in the sera of lung cancer patients with cachexia [47]. Similarly, the restablestin-like alpha (Retnla) adipokine is among the top 10 genes and is strongly associated with the inflammatory response and metabolic regulation (Supplementary Table 1). Thus, it is possible to measure Retnla in the serum [48]. Together, Ghrelin and Retnla may comprise one approach for detecting MetS-associated lung damage.

**Conclusion**

The purpose of our study was to explore the mechanism by which sucrose induces MetS in a rat model and modifies the gene expression and tissue characteristics of the lung. The rat model is characterized by an increase in and the redistribution of retroperitoneal AT, along with biochemical changes in the lipid profile and in leptin and adiponectin levels. These hormonal changes play important roles in establishing a systemic inflammatory response, which can impact the lung’s molecular physiology. The lungs exhibit an inflammatory phenotype in animals with MetS. These pathological changes are associated with molecular changes that affect several signaling pathways that are related to melatonin metabolism, olfactory receptors and cytokine production.

**Materials and methods**

**Animals**

*Control animals (CTL):* Twelve healthy male Wistar rats (Rattus norvegicus) (6 months old, 400-500 g) were used. They were fed 50-80 g of a normal rodent diet after weaning (Laboratory Rodent Diet 5001, PMI Nutrition International, Brentwood, MO) for 24 weeks, with water ad libitum; the diet consisted of 28.507% protein, 13.496% fat, and 57.996% carbohydrates HCO (3.7% sucrose, 0.3% fructose, and 0.22% glucose). When they reached a predetermined age, rats were humanely sacrificed by decapitation to obtain the blood and lungs for the experiments. Decapitation was chosen to avoid interference by the anesthetics and to enable exsanguinations. The lungs were excised and washed in cold normal Tyrode’s solution (140 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl₂, 5 mmol/L HEPES, 10 mmol/L glucose, and 1 mmol/L CaCl₂, pH 7.4). All solutions were oxygenated with 95% O₂, 5% CO₂ at 160 mmHg pO₂ and 21.3 mmHg pCO₂. Serum was obtained by blood centrifugation. All animals were housed in proper facilities in groups of 6 per cage and maintained at a controlled temperature with an artificial 12:12 hr dark-light cycle.

*Animals with metabolic syndrome (MetS)*

After weaning at 6 months of age, twelve healthy male Wistar rats were fed the normal rodent diet (Laboratory Rodent Diet 5001, PMI Nutrition International, Brentwood, MO), which consisted of 28.507% protein, 13.496% fat, and 57.996% HCO (3.7% sucrose, 0.3% fructose, and 0.22% glucose); they were also given a 30% sucrose solution as the sole liquid source for 24 weeks. These animals were middle-aged adults by the end of the treatment and were sacrificed as described for the Control group. The lungs were excised and washed in cold normal oxygenated Tyrode’s solution. To determine MetS, the body weight, fat tissue weight, blood pressure, triglycerides, total cholesterol, blood glucose, insulin and leptin concentrations were measured as previously described [21].

The MetS group fulfilled the proposed criteria for a definition of MetS for rodents [26].

Of the 25 rats used in this study, 9 (3 for the MetS group, with one technical replicate, and 4 for the control group (CTL), with one technical replicate) were used for the microarray experiment, and 16 (8 in the MetS group and 8 in the CTL group) were used for the histology and validation experiments.
Statement of animal rights and welfare

All procedures were followed in accordance with the ethical standards of the committee for responsible animal experimentation. All animals were lawfully acquired, and the animal procedures in this study was performed in accordance with “The Code of Ethics of the World Medical Association” (Declaration of Helsinki): EC Directive 86/609/EEC for animal experiments [49]. The protocol was reviewed and approved by the Ethics Committee of the National Institute of Cardiology. The experimental studies followed the guidelines of the Norma Oficial Mexicana guide for the use and care of laboratory animals (NOM-062-ZOO-1999) and for the disposal of biological residues (NOM-087-ECOL-1995).

The authors have read the International Association of Veterinary Editors’ Consensus Author Guidelines on Animal Ethics and Welfare and declare that all animals in this study were treated according to the aforementioned statement.

Determination of MetS parameters

Blood pressure measurements: Systolic arterial blood pressure measurements were obtained in conscious animals using the tail-cuff method; the cuff was connected to a pneumatic pulse transducer (Narco Bio-Systems Inc., Austin TX) and a programmed electrophysymomanometer. The recordings were taken from six independent determinations with a Grass polygraph (model 79, Grass Medical Instruments, Quincy, MA).

Determination of morphological variables

Before decapitation, each animal was weighed, and its general health status was assessed. After each animal was sacrificed, the total abdominal adipose tissue was weighed to determine obesity.

Determination of blood variables

After an overnight fast (12 hours), each animal was sacrificed by decapitation, and blood was collected. The serum was separated by centrifugation at 15,000 rpm for 15 min at 4°C and stored at -20°C until further use.

Serum insulin: Serum insulin was determined using a commercial rat-specific radioimmunoassay (RIA) kit (Linco Research, Inc. St. Charles, MO); the sensitivity was 0.1 ng/mL, and the intra- and inter-assay coefficients of variation were 5 and 10%, respectively.

Serum glucose: The glucose concentration was assessed using the commercial DCL-glucose oxidase enzymatic procedure kit (Diagnostic Chemical Limited de México, Mexico).

Serum triglycerides: Triglycerides (TGs) were determined using the commercially available SPINREACT triglycerides-LQ spectrophotometric procedures (Spinreact S. A., Girona, Spain).

Serum cholesterol: Cholesterol was determined using the commercial SPINREACT cholesterol-LQ enzymatic procedure kit (Spinreact S. A. Girona, Spain).

Homeostasis model assessment (HOMA): HOMA was used as an index to measure the degree of insulin resistance and was calculated using the following formula: (insulin (UI/mL)×glucose (mmol/L))/22.5 [50].

Serum leptin: Serum leptin was determined using a specific ELISA (enzyme-linked immunosorbent assay) kit for rat EZRL-83K (Millipore, Co, Billerica, MA); the sensitivity was 0.08 ng/mL. The intra- and inter-coefficients of variation were 2.13 and 2.95%, respectively.

Serum adiponectin: Serum adiponectin was determined using a specific ELISA (enzyme-linked immunosorbent assay) kit for rat EZRADP-62K (Millipore, Co, Billerica, MA); the sensitivity was 0.4 ng/mL. The intra- and inter-coefficients of variation were 1.59 and 6.54%, respectively.

Histological examination of the lung tissue

At the end of the sucrose treatment period, the lungs were fixed in 10% buffered formalin for less than 24 hours and stored in 70% ethanol until paraffin embedding. A portion of each tissue was frozen and protected with Tissue-Tek™, and 4- and 10-µm thick tissue sections were cut from paraffin-embedded blocks and frozen tissue, respectively, for placement onto glass slides. Hematoxylin and eosin (H&E) and Red Oil (RO) staining were performed using standard procedures (INMGEN, Histology and Confocal Microscopy Laboratory, Mexico).
Total RNA extraction

The RNA isolation from the lung tissues was performed using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions; the RNA from each sample was dissolved in a final volume of 40 μl of RNase-free. Total RNA quantifications and purity assessments were determined with a ND®-1000 spectrophotometer (Technologies, Inc. Wilmington, DE, USA). To determine the total RNA quality, the samples were measured using Agilent’s 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA). An RNA Integrity Number (RIN) ≥6 was used as a quality filter to perform the microarray assays. The samples were stored at -80°C until further processing.

Array experiment

The expression analysis was performed with the GeneChip® Rat 1.0 ST Arrays (Affymetrix, Inc., Santa Clara, CA, USA; http://www.affymetrix.com) using 50 ng of RNA per sample. The target labeling, array hybridization, washing and staining were performed as described in the GeneChip Whole Transcript (WT) Sense Target Labeling manual. The arrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix, Inc., Santa Clara, CA, USA).

Data analysis

The raw. CEL files were processed with the Robust Multichip Average (RMA) statistical model for gene expression signals [51]. This algorithm was used for the background correlation, quantile normalization and median polish summarization with the R/Bioconductor software. The comparisons between groups (L_MetS vs. L_C) were performed using R/Limma to obtain the data matrix of the differentially expressed genes that were used for the subsequent analysis [52].

Enrichment analysis

The list of differentially expressed genes was uploaded into the “Ingenuity Pathway Analysis” enrichment tool (IPA, Ingenuity, Inc.; Redwood City, CA, USA). The selection criteria for the analyses included a logarithm of fold change (logFC) ≥1.8 and a P<0.02. All data were associated with biological functions and/or diseases, networks, upstream regulators and canonical pathways.

Validation experiments by qRT-PCR

First-strand cDNA synthesis was performed using 2 μg of RNA in a 20-μl total reaction volume using 2.0 μl of 10× RT buffer, 0.8 μl of 25× dNTP mix, 2.0 μl of 10× RT Random Primers, 1.0 μl of MultiScribeTM Reverse Transcriptase, and 4.2 μl of nuclease-free water. The reaction was incubated at 25°C for 5 min, 37°C for 120 min, and 85°C for 5 min, followed by 4°C ∞. The RNA sample was stored in a 10-μl volume (Applied Biosystem, Foster City, CA, USA).

Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to measure gene expression to validate the microarray technique. TaqMan® probes were used for determining the amplification of the following target genes: Olrf482, Olrf1126, Bcl2l1, Them5 (C2-cd4d), Mrpl41, Pik3c2a, NFKBa and Scl12a2. Hrpt1 was used as the housekeeping gene. The experiments were performed in a 96-well plate from Applied Biosystems ViiA 7 (Carlsbad, CA, USA), and each sample was analyzed in duplicate. The final reactions (10 μl) were set up with 0.5 μl of TaqMan® probes, 5 μl of PCR TaqMan® Universal Master Mix, 2.5 μl of RNase-free water and 2 μl of cDNA (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. The thermal cycling conditions that were used for all reactions were as follows: Step 1, 50°C for 2 min and 95°C for 2 min; Step 2, 40 cycles of 95°C for 15 sec. The annealing conditions for the sequence-specific oligonucleotide primer were 60°C for 1 min. Gene expression was calculated using the ddCT method that was provided by the Applied Biosystems ViiA 7 software using 10 pooled control rat lungs as a reference sample. Using a method for relative expression, we determined that the fold changes of the analyzed transcripts fell between -1.36 to 4.32; the expression pattern was concordant with the results of the microarray analysis.

Acknowledgements

This work was supported by a PhD scholarship that was received by SMRP from the National Council for Science and Technology (CONACYT #230762, #324898) and by the following financial project: CONACyT, No. project 169652,
“Study of gene expression in the hypothalamus-adipose axis in a rat model with metabolic syndrome”, Project manager: Laura del Bosque-Plata, Ph.D. We are thankful for the financial support of the National Institute of Cardiology “Ignacio Chávez” (SSA) for the animal model. We also thank the Histology and Confocal Microscopy Facility and the Gene Expression and Genotyping Facility of the INMEGEN for their support of this investigation.

Disclosure of conflict of interest

None.

Address correspondence to: Laura del Bosque-Plata, Laboratorio de Nutrigenética y Nutrigenómica, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Col. Arenal Tepepan, Tlalpan, C.P. 14610, Ciudad de México, México. Tel: +52(55)53501974; E-mail: ldelbosque@inmegen.gob.mx

References


Lung RNAome modulation in metabolic syndrome


[38] Agarwal V, Bell GW, Nam JW and Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015; 4.


Lung RNAome modulation in metabolic syndrome


**Supplementary Table 1.** Top 10 molecules. Log ratio up-regulated and Log ratio down regulated

<table>
<thead>
<tr>
<th>Molecules</th>
<th>Exp. Value</th>
<th>Molecules</th>
<th>Exp. Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Them5</td>
<td>1.3</td>
<td>Loc685792</td>
<td>-2.977</td>
</tr>
<tr>
<td>H2-t22</td>
<td>0.982</td>
<td>Sult1c2</td>
<td>-2.707</td>
</tr>
<tr>
<td>Retnla</td>
<td>0.960</td>
<td>Sult2a</td>
<td>-2.369</td>
</tr>
<tr>
<td>Rpl12</td>
<td>0.940</td>
<td>Olf1306/Olf1307</td>
<td>-2.358</td>
</tr>
<tr>
<td>Trim16</td>
<td>0.769</td>
<td>Amy2b</td>
<td>-2.330</td>
</tr>
<tr>
<td>Zbtb16</td>
<td>0.735</td>
<td>Olf1245</td>
<td>-2.185</td>
</tr>
<tr>
<td>Nrn1</td>
<td>0.654</td>
<td>Olf8484</td>
<td>-2.151</td>
</tr>
<tr>
<td>Sbsn</td>
<td>0.618</td>
<td>Olf910/Olf912</td>
<td>-2.122</td>
</tr>
<tr>
<td>Scd</td>
<td>0.612</td>
<td>Olf823/Olf824</td>
<td>-2.111</td>
</tr>
<tr>
<td>Pfkfb1</td>
<td>0.611</td>
<td>Tceb1</td>
<td>-2.048</td>
</tr>
</tbody>
</table>

**Supplementary Table 2.** Top upstream regulators

<table>
<thead>
<tr>
<th>Upstream Regulator</th>
<th>p-value of overlap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gherlin</td>
<td>6.03E-03</td>
</tr>
<tr>
<td>PXR ligand-PXR-retinoic acid-RXR</td>
<td>1.94E-02</td>
</tr>
<tr>
<td>Bcl11b</td>
<td>2.45E-02</td>
</tr>
<tr>
<td>5-4-N-methyl-N2-pyridylamino ethoxybenzyl thiazolidine-2,4-dione</td>
<td>2.50E-02</td>
</tr>
<tr>
<td>Slc34a3</td>
<td>2.52E-02</td>
</tr>
</tbody>
</table>